Division of Experimental Vitreoretinal Surgery, Centre for Ophthalmology, University of Tuebingen, Tübingen, Germany.
STZ Ocutox - Preclinical Drug Assessment, Hechingen, Germany.
Pharmacol Res Perspect. 2020 Dec;8(6):e00683. doi: 10.1002/prp2.683.
Age-related macular degeneration (AMD) is the leading cause of blindness in older people in the developed world while Stargardt's disease (SD) is a juvenile macular degeneration and an orphan disease. Both diseases are untreatable and are marked by accumulation of lipofuscin advancing to progressive deterioration of the retinal pigment epithelium (RPE) and retina and subsequent vision loss till blindness. We discovered that a small molecule belonging to the tetrahydropyridoether class of compounds, soraprazan renamed remofuscin, is able to remove existing lipofuscin from the RPE. This study investigated the drug penetration, distribution, and elimination into the eyes of a mouse model for increased lipofuscinogenesis, following a single intravitreal injection. We measured the time course of concentrations of remofuscin in different eye tissues using high-performance liquid chromatography combined with mass spectroscopy (HPLC-MS). We also visualized the penetration and distribution of H-remofuscin in eye sections up to 20 weeks post-injection using transmission electron microscopic (TEM) autoradiography. The distribution of silver grains revealed that remofuscin accumulated specifically in the RPE by binding to the RPE pigments (melanin, lipofuscin and melanolipofuscin) and that it was still detected after 20 weeks. Importantly, the melanosomes in choroidal melanocytes only rarely bind remofuscin emphasizing its potential to serve as an active ingredient in the RPE for the treatment of SD and dry AMD. In addition, our study highlights the importance of electron microscopic autoradiography as it is the only method able to show drug binding with a high intracellular resolution.
年龄相关性黄斑变性(AMD)是发达国家老年人致盲的主要原因,而斯塔加德病(SD)是一种青少年黄斑变性和孤儿病。这两种疾病都是无法治愈的,其特征是脂褐素的积累,导致视网膜色素上皮(RPE)和视网膜的进行性恶化,随后视力下降直至失明。我们发现,属于四氢吡啶醚类化合物的一种小分子,即索拉嗪(soraprazan),更名为雷莫福辛(remofuscin),能够从 RPE 中去除现有的脂褐素。本研究通过单次玻璃体内注射,研究了一种增加脂褐素生成的小鼠模型中,药物穿透、分布和消除进入眼睛的情况。我们使用高效液相色谱-质谱联用(HPLC-MS)法测量了雷莫福辛在不同眼部组织中的浓度随时间的变化。我们还使用透射电子显微镜(TEM)放射自显影术,在注射后长达 20 周的时间内,对 H-雷莫福辛在眼部切片中的穿透和分布进行了可视化。银颗粒的分布表明,雷莫福辛通过与 RPE 色素(黑色素、脂褐素和黑素脂褐素)结合而特异性地在 RPE 中积累,并且在 20 周后仍能检测到。重要的是,脉络膜黑素细胞中的黑素体很少与雷莫福辛结合,这强调了它作为 SD 和干性 AMD 中 RPE 治疗活性成分的潜力。此外,我们的研究强调了电子显微镜放射自显影术的重要性,因为它是唯一能够以高细胞内分辨率显示药物结合的方法。